The agreement with Hikma Pharmaceuticals is likely to have a positive short-term impact on Collegium's stock price. By securing an exclusive partner for the sale of Nucynta's authorized generics, Collegium ensures a continued revenue stream from these products. The deal also mitigates the risk of revenue loss due to generic competition, as Collegium will receive a share of net profits, although this may decrease with more generic entrants. The partnership with an industry leader like Hikma underscores Collegium's commitment to maintaining the Nucynta Franchise's value and accessibility, potentially boosting investor confidence.